All AbMole products are for research use only, cannot be used for human consumption.
Albiglutide is a recombinant fusion protein consisting of two copies of a 30-amino-acid sequence of modified human GLP-1 (fragment 7-36), modified with a glycine substituted for the naturally occurring alanine at position 8 in order to augment resistance to DPP-4.
Sequence: His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH2
| Molecular Weight | 3283.6 |
| Formula | C148H224N40O45 |
| CAS Number | 782500-75-8 |
| Solubility (25°C) | Water 90 mg/mL |
| Storage | -20°C, dry, sealed |
[1] Marc S Rendell. Expert Opin Biol Ther. Albiglutide: a unique GLP-1 receptor agonist
| Related GLP Receptor Products |
|---|
| 3-Deoxyglucosone
3-Deoxyglucosone (3-Deoxy-D-glucosone) is a reactive intermediate of the Maillard reaction and the polyol pathway. 3-Deoxyglucosone rapidly reacts with protein amino groups to form advanced glycation end products (AGEs). 3-Deoxyglucosone inactivates glutathione peroxidase and synergizes with low glucose to enhance GLP-1 secretion. 3-Deoxyglucosone is used as a biomarker for diabetes mellitus. |
| V-0219 hydrochloride
V-0219 hydrochloride is an orally active, positive allosteric modulator (PAM) of the glucagon-like peptide-1 receptor (GLP-1R). |
| GLP-1 receptor agonist 14
GLP-1 receptor agonist 14 is a potent agonist of glucagon-like peptide-1 (GLP-1). |
| NM-003
NM-003 is a GLP-2R agonist that can be used in studies related to inflammatory bowel disease. |
| NB-1002
NB-1002 is a GLP-2R agonist that can be used in studies related to short bowel syndrome. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
